The Development of IPV

  • A. John Beale


Jonas Salk died on 23 June 1995, and so is prevented from writing about the ­development of what he called “non-infectious polio vaccine”. My credentials to undertake the task are not perfect. I never worked for Jonas directly and by the time I reached Toronto to take up a Research Fellowship in Virus Diseases under the directions of Dr. Andrew Rhodes at the Hospital for Sick Children in September 1954, the Francis Trial of injectable polio vaccine (IPV) was already in progress.

Toronto, at the time of working for Andrew Rhodes, was an excellent place to observe the development of both IPV and oral polio vaccine (OPV). Rhodes in 1947 had set up a polio research unit at the Connaught Laboratories associated with the School of Hygiene of the University of Toronto. This unit was to play a decisive role in the development of IPV.


Yellow Fever Simian Virus Oral Polio Vaccine High Titre Virus Paralytic Poliomyelitis 


  1. 1.
    Kolmer JA. Vaccination against acute anterior poliomyelitis. Am J Public Health 1936;26:125–35Google Scholar
  2. 2.
    Brodie M, Park WH. Active immunisation against poliomyelitis. Am J Public Health 1936;26:119–25CrossRefGoogle Scholar
  3. 3.
    Sabin AB, Olitsky PK. Cultivation of poliomyelitis virus in human embryonic nervous tissue. Proc Soc Exp Biol Med 1936;31:357–9Google Scholar
  4. 4.
    Burnet FM, McNamara J. Immunological differences between strains of poliomyelitis virus. Br J Ex Path 1931;12:57–61Google Scholar
  5. 5.
    Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949;109:234–45CrossRefGoogle Scholar
  6. 6.
    Bodian D. Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses; the grouping of fourteen strains into three basic immunologic types. Am J Hyg 1949;49:234–45PubMedGoogle Scholar
  7. 7.
    Salk J. Poliomyelitis Vaccine in the fall of 1955. Am J Public Health 1956;46:1–14CrossRefGoogle Scholar
  8. 8.
    Van Riper HE. Progress in the control of paralytic poliomyelitis through vaccination. Can J Public Health 1955;46:427–48Google Scholar
  9. 9.
    Morgan JF, Morton HJ, Parker RC. Nutrition of animal cells in tissue culture. 1. Initial studies on a synthetic medium. Proc Soc Exp Biol and Med 1950;73:1–8Google Scholar
  10. 10.
    Maitland HB, Maitland MC. Cultivation of vaccinia virus without tissue culture. Lancet 1928;2:596–7Google Scholar
  11. 11.
    Wood W, Shimada FT. Isolation of strains of Virus B from tissue cultures of cynomolgus and rhesus kidney. Can J Publ Hlth 1954;45:509–18Google Scholar
  12. 12.
    Farrell LN, Wood W, Franklin RE, Shimada F, Macmorine H, Rhodes AJ. Cultivation of poliomyelitis virus in tissue culture: VI methods for quantity production of poliomyelitis viruses in cultures of monkey kidney. Can J Public Health 1953;44:273–80PubMedGoogle Scholar
  13. 13.
    Francis TM Jr, Napier JA, Voight RB et al. Evaluation of the 1954 field trial of poliomyelitis vaccine. Final Report Ann Arbor University of Michigan 1957Google Scholar
  14. 14.
    Fantes KH. Concentrations and partial purification of poliomyelitis viruses. J Hygiene 1962;60:123–33CrossRefGoogle Scholar
  15. 15.
    LeBouvier GL. The D to C change in poliovirus particles. Br J Exper Path 1959;40:605–20Google Scholar
  16. 16.
    Beale AJ. The D-antigen content in polio vaccine as a measure of potency. Lancet 1961;2:1166–8Google Scholar
  17. 17.
    Hull R, Minner JR, Mascoli GC. New agents recovered from tissue culture of monkey kidney cells: III Recovery of additional agents both from cultures of monkey kidney tissues and directly from tissues and excreta. Am J Hyg 1959;68:31–44Google Scholar
  18. 18.
    Sweet DH, Hilleman MR. The vacoulating virus, SV40. Proc Soc Exp Biol Med 1960;105:420–7Google Scholar
  19. 19.
    Van Wesel AL4, van Steenis G, van der Marel P, Osterhouse ADM. Inactivated poliovirus ­vaccine: current production methods and new developments. Rev Infect Dis 1984; 6 (suppl 2):335–40Google Scholar
  20. 20.
    Montagnon B, Fanget B, Vincent-Falguet JC. Industrial scale production of inactivated ­poliovirus vaccine prepared by culture of Vero cells and microcarriers. Rev Infect Dis 1984;6S:341–4Google Scholar
  21. 21.
    Beale AJ, Mason PJ, The measurement of D-antigen in poliovirus preparations. J Hyg 1962;60 :113–21CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • A. John Beale
    • 1
  1. 1.BeckenhamUK

Personalised recommendations